Los Angeles Capital Management LLC Has $94.74 Million Position in Stryker Co. (NYSE:SYK)

Los Angeles Capital Management LLC reduced its stake in Stryker Co. (NYSE:SYK) by 25.6% during the fourth quarter, HoldingsChannel reports. The firm owned 316,363 shares of the medical technology company’s stock after selling 108,894 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Stryker were worth $94,738,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Stryker by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 30,665,520 shares of the medical technology company’s stock valued at $8,379,967,000 after purchasing an additional 143,631 shares in the last quarter. FMR LLC boosted its position in Stryker by 2.5% during the 3rd quarter. FMR LLC now owns 5,972,582 shares of the medical technology company’s stock worth $1,632,127,000 after buying an additional 144,208 shares during the period. Morgan Stanley boosted its position in Stryker by 4.4% during the 3rd quarter. Morgan Stanley now owns 5,315,227 shares of the medical technology company’s stock worth $1,452,493,000 after buying an additional 223,728 shares during the period. Fisher Asset Management LLC boosted its position in Stryker by 2.6% during the 4th quarter. Fisher Asset Management LLC now owns 4,042,317 shares of the medical technology company’s stock worth $1,210,512,000 after buying an additional 103,326 shares during the period. Finally, Northern Trust Corp boosted its position in Stryker by 3.9% during the 3rd quarter. Northern Trust Corp now owns 3,505,595 shares of the medical technology company’s stock worth $957,974,000 after buying an additional 131,590 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Trading Down 0.3 %

Shares of NYSE:SYK traded down $0.91 during mid-day trading on Thursday, hitting $327.21. The company had a trading volume of 1,033,797 shares, compared to its average volume of 1,315,318. The firm has a fifty day moving average price of $348.05 and a 200 day moving average price of $316.78. The company has a market capitalization of $124.49 billion, a PE ratio of 37.46, a price-to-earnings-growth ratio of 2.71 and a beta of 0.91. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97. Stryker Co. has a one year low of $249.98 and a one year high of $361.41.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share for the quarter, beating the consensus estimate of $2.36 by $0.14. The company had revenue of $5.24 billion during the quarter, compared to analyst estimates of $5.10 billion. Stryker had a net margin of 16.03% and a return on equity of 23.44%. Stryker’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.14 EPS. As a group, research analysts forecast that Stryker Co. will post 11.86 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th were paid a dividend of $0.80 per share. The ex-dividend date was Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a yield of 0.98%. Stryker’s dividend payout ratio (DPR) is presently 36.53%.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Robert W. Baird lifted their target price on shares of Stryker from $367.00 to $378.00 and gave the stock an “outperform” rating in a research report on Wednesday. Canaccord Genuity Group upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $360.00 target price on the stock in a research report on Wednesday, January 31st. Royal Bank of Canada lifted their target price on shares of Stryker from $360.00 to $386.00 and gave the stock an “outperform” rating in a research report on Monday, April 15th. UBS Group lifted their target price on shares of Stryker from $339.00 to $351.00 and gave the stock a “neutral” rating in a research report on Wednesday. Finally, Evercore ISI boosted their price target on shares of Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $357.05.

Insider Buying and Selling at Stryker

In other Stryker news, Director Allan C. Golston sold 3,273 shares of the business’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now owns 14,242 shares in the company, valued at approximately $4,856,522. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Stryker news, Director Allan C. Golston sold 3,273 shares of the business’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now owns 14,242 shares in the company, valued at approximately $4,856,522. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the transaction, the chief accounting officer now directly owns 3,675 shares in the company, valued at $1,317,414. The disclosure for this sale can be found here. In the last 90 days, insiders sold 212,109 shares of company stock worth $72,845,768. 5.90% of the stock is owned by corporate insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.